RxDoctor Payments Data

Patricia Pritchett

Family · Oak Ridge, TNNPI 1427578830

Payments from drug & device makers

$3,715in general payments, 2019–2025

Across 148 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$346
  • Sumitomo Pharma America, Inc.$340
  • Boston Scientific$331
  • Johnson & Johnson$301
  • Urovant Sciences Inc$254
  • Urogen Pharma, Inc.$213
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,65698%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,715 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$276,921
Medicare patients
952
Services billed
18,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron138$108,713
GemtesaVibegron105$96,492
Solifenacin Succinate199$15,353
Tamsulosin Hcl722$10,752
Silodosin43$4,294
Finasteride319$3,424
Alfuzosin Hcl ErAlfuzosin Hcl177$3,192
Oxybutynin Chloride ErOxybutynin Chloride95$2,964
Potassium Citrate ErPotassium Citrate24$2,669
Cefdinir116$1,847
Tolterodine Tartrate ErTolterodine Tartrate18$1,740
Fesoterodine Fumarate ErFesoterodine Fumarate15$1,732
Testosterone12$1,711
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst61$1,704
Testosterone Cypionate29$1,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$123$108,713138 claims
Sumitomo Pharma America, Inc.Gemtesa$340$96,492105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →